{
    "2018-10-15": [
        [
            {
                "time": "",
                "original_text": "看好评级医药生物行业2018年三季报业绩前瞻：医药需求刚性 预计增长保持稳健",
                "features": {
                    "keywords": [
                        "医药",
                        "生物",
                        "三季报",
                        "业绩",
                        "需求刚性",
                        "增长",
                        "稳健"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-12",
                "original_text": "【申万宏源医药闫一天团队】20181012周观点：医药需求刚性，预计增长保持稳健——医药生物行业2018年三季报业绩前瞻",
                "features": {
                    "keywords": [
                        "申万宏源",
                        "医药",
                        "三季报",
                        "需求刚性",
                        "增长",
                        "稳健"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药健康行业周报：科伦药业产业布局深度点评",
                "features": {
                    "keywords": [
                        "医药健康",
                        "科伦药业",
                        "产业布局",
                        "深度点评"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药健康"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "华兰生物：目前国内的四价流感疫苗为公司独家供应",
                "features": {
                    "keywords": [
                        "华兰生物",
                        "四价流感疫苗",
                        "独家供应"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "47股获券商买入评级，利亚德目标涨幅达153.49%",
                "features": {
                    "keywords": [
                        "券商",
                        "买入评级",
                        "利亚德",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "多元行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-10-15",
                "original_text": "【太平洋证券今日早读】固收：利率债短端机会更大，密切关注政策转向的可能性|华兰生物、联得装备公司点评20181015",
                "features": {
                    "keywords": [
                        "太平洋证券",
                        "固收",
                        "利率债",
                        "政策转向",
                        "华兰生物",
                        "联得装备"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "固收",
                        "医药",
                        "装备制造"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}